Many CIMs present “addressable patient population,” “peak sales potential,” or “differentiated platform” without proving clinical-stage probability of success, a regulatory pathway that survives an AdCom, composition-of-matter IP that survives a Paragraph IV challenge, or manufacturing that survives a Form 483. Biotech and pharmaceutical due diligence (also called pharma, drug development, clinical-stage, life sciences, medical device, API, CDMO, or therapeutics diligence) underwrites how the business discovers, develops, manufactures, and commercializes regulated products. It tests clinical-stage and pipeline risk, regulatory pathway, IP moat and cliff, manufacturing reliance, payer access, exclusivity economics, and post-approval safety. It is not the same as healthcare services diligence (facilities, providers, HIPAA, RCM), technology diligence (engineering stack alone), SaaS diligence (ARR/NRR metrics), compliance diligence (internal program alone), IP diligence (portfolio listing alone), quality of earnings (accounting alone), or commercial diligence (aggregate demand). Biotech work underwrites whether the drug-development engine produces approvable, reimbursable, defensible products through the hold period.
Biotech vs healthcare services vs technology vs compliance
| Workstream | Primary question | Typical output |
|---|---|---|
| Biotech / pharma DD | Is the drug-development engine bankable? | Pipeline risk map, IP cliff, payer bridge, CMO reliance |
| Healthcare services DD | Are facility, provider, and payer operations sound? | Payer mix, RCM, HIPAA, staffing |
| Technology DD | Is the engineering stack and architecture sound? | Code, debt, team, infra |
| SaaS metrics DD | Are ARR/NRR definitions durable? | Cohorts, retention, packaging |
| Compliance / IP program DD | Is the control or IP program effective? | Policies, portfolio listing, screening |
Six pillars of biotech & pharmaceutical diligence
1. Clinical-stage risk & pipeline probability
Bridge headline “peak sales” and “addressable patients” to real-world approval probability: indication and trial design, primary and secondary endpoints, blinded vs open-label data, futility and stopping rules, comparator arms, enrollment and site concentration, historical phase success rates by modality (small molecule, biologic, cell/gene, device), and how much enterprise value rides on a single near-term readout. Align with commercial diligence, market diligence, and management diligence when platform claims drive the thesis.
2. Regulatory pathway & FDA interactions
Pre-IND and Type A/B/C meeting history, special designations (Fast Track, Breakthrough, PRMA/RMAT, orphan, QIDP, Regenerative Medicine Advanced Therapy), accelerated vs full approval basis, SPA agreements, advisory committee risk, complete response letters and refusal-to-file history, post-marketing requirements, and global pathway (EMA centralized, PMDA, NMPA) through the hold period. Connect to regulatory, compliance, legal, and QoE workstreams when milestone revenue and contingent payments are in play.
3. IP moat, Orange Book & freedom-to-operate
Composition-of-matter versus method-of-use versus formulation patents, Orange Book listing completeness for approved products, remaining patent and regulatory exclusivity (NCE, ODE, orphan, pediatric, PTE), Paragraph IV and IPR/PTAB exposure, biosimilar and generic entry timing, freedom-to-operate versus competitors, trade-secret protection for cell-line and process know-how, and whether the platform IP actually covers the lead assets. Connect to IP diligence, legal, technology, and contract diligence.
4. CMO/CDMO manufacturing, CMC & supply
Single-source versus dual-sourced API and drug-product manufacturing, FDA inspection history (Form 483, warning letters, consent decrees, import alerts), cold-chain and logistics, batch-failure and release rates, capacity and slot commitments, raw-material (cell line, media, reagent) sole-supplier risk, change-of-control and technology-transfer consent rights, and whether the buyer can replicate production without re-approval. Connect to operational, supply-chain, BCP / DR, and cybersecurity workstreams.
5. Payer access, reimbursement & pricing power
List price versus net price after rebates, gross-to-net erosion trend, formulary tier and step-therapy, Medicare Part B/D coverage and coding (J-code, HCPCS), Medicaid drug rebate program liability, 340B participation and compliance, international reference pricing and IRA negotiation exposure, payer evidence requirements and HEOR strategy, companion-diagnostic co-dependency, and whether reimbursement authority depends on a single label or indication. Align with commercial, pricing, financial, and competitive diligence.
6. Exclusivity cliffs, KOL concentration & pharmacovigilance
Orphan and exclusivity calendar through hold period, key opinion leader and principal-investigator concentration with conflict-of-interest and Sunshine Act exposure, post-approval safety (REMS, pharmacovigilance, signal detection, label-expansion risk), litigation and product-liability exposure, and go-forward control of clinical, regulatory, and manufacturing talent. Connect to management, people, board / governance, cultural, and LBO diligence.
DI20-WELCOME) — useful for pipeline and clinical-stage questions, FDA pathway red flags, IP cliff and freedom-to-operate maps, CMO/CDMO and inspection risks, payer access and exclusivity cliffs, and data-room prioritization, not a substitute for full clinical expert reviews, regulatory counsel, patent opinions, CMC audits, or pharmacovigilance assessments.
Stage sequencing (screen to IC)
| Stage | Biotech focus | Deal-team action |
|---|---|---|
| Teaser / CIM | Peak sales, platform story, readout calendar | Flag single-readout binary risk, IP cliff, CMO reliance |
| Desk diligence | Approval probability, FDA interactions, Orange Book | Red/amber/green; hotspot list |
| Deep clinical / regulatory / legal | Experts, counsel, CMC audit, payer map | Pipeline bridge; IP & exclusivity map |
| IC / model | Cases for CRL, failed readout, generic entry, payer cut | Base / upside / downside with binary cliffs |
| Post-close | Tech transfer, KOL retention, pharmacovigilance | 100-day biotech control plan with named owners |
Red flags
| Signal | Severity | Why it matters |
|---|---|---|
| Majority of enterprise value tied to a single near-term clinical readout | Deal-Killer | Binary outcome the buyer cannot de-risk |
| Composition-of-matter absent or expired on lead asset; only method/formulation IP remains | Deal-Killer | Generic/biosimilar entry before hold exit |
| Sole-source CMO with active warning letter or import alert on the only revenue product | Deal-Killer | Supply stoppage is enterprise-ending |
| Reimbursement rests on a single label/indication with payer review pending | High | Revenue collapse faster than patent cliff |
| Open or recent Complete Response Letter on lead asset | High | Approval timeline and cost reset |
| Orphan exclusivity or NCE exclusivity expires mid-hold without label expansion | High | Competitive entry cliff inside the model |
| Lead KOL/PI is a founder with undisclosed conflicts and Sunshine Act exposure | High | Data integrity and credibility risk |
| IRA negotiation or international reference pricing materially resets net price | Watch | Model and IC risk elevated |
Cost & timeline (traditional vs first-pass)
| Approach | Typical cost | Timeline | Best use |
|---|---|---|---|
| Full biotech specialist module (clinical, regulatory, IP, CMC, payer, PV) | $50K–$250K+ | 6–16 weeks | Lead-asset acquisitions, platform companies, cross-border approvals |
| Targeted clinical + IP + CMO + payer deep-dive | $25K–$100K | 3–8 weeks | Single late-stage asset or commercial-stage product |
| Public first-pass biotech & pharmaceutical pack | $49 | Minutes to hours | Triage before specialist spend / IC framing |
50-point biotech & pharmaceutical diligence checklist
- Modality: small molecule, biologic, cell/gene therapy, medical device, diagnostic, platform
- Lead asset indication, line of therapy, and patient population
- Trial design: phase, blinding, endpoints, comparator, duration
- Primary endpoint statistical powering and futility rules
- Open-label vs blinded data quality and interim-readout risk
- Enrollment status, site concentration, and geographic mix
- Historical phase success rate for modality and indication
- Enterprise value tied to nearest readout (% and timing)
- FDA interactions: pre-IND, Type A/B/C, SPA, AdCom history
- Special designations: Fast Track, Breakthrough, RMAT, orphan, QIDP, PRMA
- Accelerated vs full approval basis and confirmatory trial status
- Complete response letters, refusal-to-file, or enforcement history
- Global pathway: EMA centralized, PMDA, NMPA, Health Canada
- Composition-of-matter patent coverage on lead asset
- Method-of-use and formulation patents: scope and remaining term
- Orange Book / Purple Book listing completeness
- Remaining NCE, ODE, orphan, pediatric, and PTE exclusivity
- Paragraph IV certifications and IPR/PTAB challenges
- Biosimilar or generic entry timing vs hold-period exit
- Freedom-to-operate opinion versus competitor IP
- Trade-secret protection for cell line, process, and know-how
- Platform IP coverage of pipeline assets beyond lead
- API and drug-product manufacturer(s): single vs dual source
- FDA inspection history: Form 483, warning letters, consent decrees, import alerts
- Cold-chain, logistics, and batch-release reliability
- Capacity and slot commitments through hold period
- Sole-supplier raw-material (cell line, media, reagent) risk
- Change-of-control and technology-transfer consent rights
- List price vs net price after rebates and gross-to-net trend
- Formulary tier, step-therapy, and prior-authorization status
- Medicare Part B/D coding (J-code, HCPCS) and coverage
- Medicaid drug rebate program and 340B exposure
- IRA negotiation and international reference-pricing risk
- Payer evidence requirements and HEOR / RWE strategy
- Companion-diagnostic co-dependency and reimbursement
- Orphan and exclusivity calendar through hold period
- Key opinion leader and principal-investigator concentration
- Conflict-of-interest and Sunshine Act exposure
- Post-approval safety: REMS, pharmacovigilance, signal detection
- Label-expansion opportunity and required trials
- Product-liability and litigation history
- Milestone and royalty obligations on approval/sales
- Collaboration, license, and co-promotion agreements
- Change-of-control clauses in licenses and grants (NIH, SBIR)
- Key clinical, regulatory, CMC, and commercial talent retention
- Data privacy for patient-level trial and real-world data
- Cyber posture for trial databases, eTMF, and manufacturing systems
- Business continuity for single-site manufacturing and cold chain
- Tax structure for IP, transfer pricing, and intangible migration
- IC materials: CRL, failed readout, generic entry, payer cut downside cases
- Post-close 100-day biotech control plan with named owners
How deal teams use a first-pass pack
Use a first-pass biotech and pharmaceutical pack to structure early questions, pressure-test CIM peak-sales and platform language, build clinical-stage and IP-cliff heat maps, and prioritize data-room asks before clinical experts, regulatory counsel, patent attorneys, CMC consultants, and payer analysts engage. Pair it with healthcare services, technology, IP, regulatory, compliance, commercial, financial, QoE, and LBO workstreams. It is an input to IC framing — not a full clinical expert review, regulatory counsel opinion, patent opinion, CMC audit, or pharmacovigilance assessment.
Underwrite the drug-development engine before you underwrite the peak-sales story
⇧ Already delivered: Tesla (TSLA) · Alphabet (GOOGL) · Palantir (PLTR) — real orders, real SEC data, every claim source-cited.
Get a structured first-pass diligence pack — useful input for biotech and pharma thesis tests, clinical-stage and IP questions, FDA pathway risk, CMO/CDMO reliance, payer access and exclusivity cliffs, and IC prep, not a full specialist biotech study.
Order report $39.20 → Free brief Sample PDF